https://www.selleckchem.com/products/canagliflozin.html Little is known about adherence to asthma biologics. Is adherence to inhaled corticosteroid (ICS) associated with subsequent asthma biologic adherence? We analyzed individuals with asthma who started asthma biologics in the OptumLab Data Warehouse and used that data until October 2019. We calculated proportion days covered (PDC) for ICS ± long-acting β-agonists in the 6months before and after asthma biologics were started and asthma biologic PDC for the first 6months of use. We performed a multivariable analysis to identify factors associated with asthma biologic PDC≥0.75, ICS PDC≥0.75 during the 6-month period after asthma biologic were started, and achievement of a≥50%reduction in asthma exacerbations during the first 6months of asthma biologic use. We identified 5,319 people who started asthma biologics. The mean PDC for asthma biologics was 0.76 (95%CI, 0.75-0.77) in the first 6months after starting, higher than the mean PDCs for ICS in the 6months before (0.44 [95%CI, 0.43-0.45]) and after (0.40 [95%CI, 0.39-0.40]) starting the asthma biologic. PDC≥0.75 for ICS 6months before index biologic use is associated with PDC for asthma biologics≥0.75 (OR, 1.25; 95%CI, 1.10-1.43) and for ICS during the first 6months of biologic use (OR, 9.93; 95%CI, 8.55-11.53). Neither ICS PDC≥0.75 (OR, 0.92; 95%CI, 0.74-1.14) nor asthma biologic PDC≥0.75 (OR, 1.15; 95%CI, 0.97-1.36) is associated with a statistically significant reduction in asthma exacerbations during the first 6months of asthma biologic use among people with any exacerbation in the 6months before first use. Adherence to asthma biologic is higher than to ICS and is associated with different factors. Adherence to asthma biologic is higher than to ICS and is associated with different factors.The Coronavirus disease-2019 (COVID-19) pandemic is an unprecedented health care crisis and has led to over 1.5 million deaths worldwide. The risk of severe COVID-19 and morta